Medical education review • Updated 10 November 2026. Not a substitute for individualized clinical assessment and local prescribing guidance.
Introduction
Corticosteroids include glucocorticoids with anti-inflammatory, immunomodulatory and metabolic actions and mineralocorticoids that regulate sodium and potassium handling. Pharmacologic effects differ by potency, biologic duration, mineralocorticoid activity, route and tissue exposure [1,2].
Classification and equivalent anti-inflammatory activity
Approximate oral glucocorticoid equivalence commonly used for education: hydrocortisone 20 mg ≈ prednisone/prednisolone 5 mg ≈ methylprednisolone 4 mg ≈ dexamethasone 0.75 mg. These are approximate anti-inflammatory equivalents, not safe automatic substitutions for all indications. Hydrocortisone has significant mineralocorticoid effects; dexamethasone has minimal mineralocorticoid activity and a long biological duration. Fludrocortisone is chiefly used for mineralocorticoid replacement [1].
Molecular mechanism
Glucocorticoids bind cytosolic glucocorticoid receptors, which regulate transcription of numerous anti-inflammatory and metabolic genes. Effects involve suppression of inflammatory transcription pathways including NF-κB and AP-1, reduced cytokine signaling, and changes in leukocyte trafficking. Some actions arise rapidly and are not solely transcriptional. Mineralocorticoid receptor activation promotes distal nephron sodium retention and potassium/hydrogen excretion [1].
Major clinical indications
Systemic glucocorticoids are used for indicated autoimmune/inflammatory diseases, severe asthma or COPD exacerbations, specific allergic reactions, cerebral edema, some hematologic diseases and hormone replacement in adrenal insufficiency. In anaphylaxis, intramuscular epinephrine is first-line and corticosteroids must not delay it. Inhaled corticosteroids are central to asthma prevention regimens, while topical agents are selected by potency, site and duration. Indication and route determine dosing and taper decisions [1].
Pharmacokinetics and interactions
Prednisone is converted hepatically to active prednisolone; impaired metabolism may affect selection. Most agents undergo hepatic metabolism and can interact with strong CYP3A inhibitors/inducers. Ritonavir or cobicistat can markedly increase exposure to certain inhaled, nasal or injected corticosteroids (notably fluticasone), causing iatrogenic Cushing syndrome and adrenal suppression. Inflammatory disease, obesity, liver dysfunction and concomitant medicines modify exposure [1].
Adverse effects and monitoring
Dose- and duration-dependent effects include hyperglycemia, hypertension, fluid retention, mood and sleep disturbance, myopathy, infection risk, osteoporosis, cataracts, glaucoma, poor wound healing and HPA-axis suppression. Long-term therapy warrants assessment of fracture risk, blood pressure, glycemia, infection prevention and appropriate bone protection. Topical corticosteroids can cause skin atrophy and other local adverse effects; inhaled use can cause oral candidiasis, reduced by rinsing after appropriate products [1,2].
Tapering and adrenal insufficiency
The joint 2024 Endocrine Society/European Society of Endocrinology guideline states that systemic glucocorticoid therapy for less than 3–4 weeks generally does not need tapering solely to prevent adrenal insufficiency, regardless of dose, although disease-specific reasons may differ. For longer courses, taper only when the underlying illness is controlled and glucocorticoids are no longer required, approaching physiologic replacement (approximately 4–6 mg prednisone/day), then taper further or assess morning cortisol as clinically appropriate. Do not routinely test adrenal function while patients remain on supraphysiologic doses. Patients with current/recent exposure and uncertain adrenal recovery require instruction about stress dosing and emergency management [2].
Practical safety
Never abruptly stop long-term systemic corticosteroids in someone at risk of adrenal suppression. Steroid withdrawal symptoms may resemble relapse or adrenal insufficiency; assess severity. In suspected adrenal crisis, urgent parenteral hydrocortisone and fluid resuscitation take priority over confirmatory testing [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- European Society of Endocrinology and Endocrine Society. Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. Joint clinical practice guideline. 2024. Available from: https://www.endocrine.org/clinical-practice-guidelines/glucocorticoid-induced-adrenal-insufficiency
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.